Patrick is a vascular biologist and the CSO of Diagonal Therapeutics. Patrick joined from Pfizer where he most recently served as Vice President, CardioRenal Discovery. Prior to Pfizer, he served as Vice President, Biology at Acceleron Pharma through its acquisition by Merck. At Pfizer and Acceleron, Patrick led discovery programs and was instrumental in providing mechanistic proof of concept and translational assessments for the cardiac and pulmonary franchises, respectively. Before his tenure at Acceleron, Patrick was the Vice President, Biology and Pharmacology at Pliant Therapeutics, focusing on the development of therapeutics for TGFβ -mediated fibrotic diseases. Earlier in his career, Patrick spent over 15 years leading cardiometabolic disease programs at Merck and Portola Pharmaceuticals. Patrick earned his Ph.D. in molecular and cellular biology of the blood vessel wall at Paris VII University and performed his research fellowship at Harvard Medical School.